Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

PURPOSE: Objective responses are reported in 34% to 37% of patients with programmed death-1 (PD-1)–naïve advanced melanoma treated with PD-1 inhibitors. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature correlate with response to PD-1 blockade. Here, we report a phase Ib/II stu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Davar, Diwakar, Wang, Hong, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien J., Ka, Mignane, Menna, Carmine, Rose, Amy, Sander, Cindy, Borhani, Amir A., Karunamurthy, Arivarasan, Tarhini, Ahmad A., Tawbi, Hussein A., Zhao, Qing, Moreno, Blanca H., Ebbinghaus, Scott, Ibrahim, Nageatte, Kirkwood, John M., Zarour, Hassane M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2018
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286160/
https://ncbi.nlm.nih.gov/pubmed/30359157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00632
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia